Editor's note

This ExpertREACT article was originally published on 25 January 2011. Pipeline data and market positions described reflect the state of knowledge at that date.

Provenge: the catalyst for renewed interest

The FDA's approval of Dendreon's Provenge (sipuleucel-T) in April 2010 - the first therapeutic cancer vaccine approved anywhere in the world - provided the field with significant commercial momentum entering 2011. Approved for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer, Provenge demonstrated that active immunotherapy could translate from laboratory concept to viable commercial product. VacZine Analytics conducted a new analysis of the therapeutic vaccine field and updated its VaccineSTATS database - previously limited to prophylactic vaccines - to cover therapeutic approaches across oncology, cardiovascular, neurological and autoimmune indications.

Defining the scope of "therapeutic vaccines" presented an early analytical challenge. Active immunotherapies inducing an antigen-specific response - for example against tumour antigens - were included, while passive immunotherapy approaches (monoclonal antibodies, antibody-drug conjugates) were excluded as they were engineered ex-vivo and did not constitute vaccines by the conventional definition. Non-specific immunomodulators using antisense drugs or oligonucleotides were similarly excluded. The question of whether autologous cell-based approaches (such as Provenge itself) strictly constituted "vaccines" in the traditional sense was also noted as a definitional boundary issue.

Clinical vaccine programmes (2011)
121
Total vaccine projects in clinical development as of VacZine Analytics' August 2009 review; the updated 2011 database included therapeutic approaches for the first time

GSK leading among major players

Among the established major vaccine players, GSK Biologicals was identified as giving the therapeutic sector the most attention with candidates in advanced clinical development. The MAGE-A3 ASCI programme for both melanoma and NSCLC and the herpes zoster programme were highlighted as near-term clinical milestones. Broader assessment of the landscape suggested most therapeutic vaccine activity remained at early academic and Phase I stages, scattered across a diverse range of oncology, Alzheimer's disease and cardiovascular indications. The high unmet need in these chronic conditions and the commercial precedent set by Provenge were expected to encourage further investment, but a realistic assessment acknowledged that the vast majority of early-stage programmes would not reach commercialisation.